Skip to content

A Multicenter randomized comparative study to evaluate the efficacy and safety of Ambroxol Hydrochloride in Elderly Individuals

A Multicenter randomized comparative study to evaluate the efficacy and safety of Ambroxol Hydrochloride in Elderly Individuals - REViVE Study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031250498
Enrollment
40
Registered
2025-11-12
Start date
2025-11-15
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none

Interventions

Intervention period: 3 months Types of intervention: 1) Active treatment and exercise therapy group: Ambroxol hydrochloride 45 mg administered orally once daily. Exercise therapy (resistance training
Sukonavi will be used solely for data collection purposes. 3) Placebo and exercise therapy group: Placebo tablets administered orally once daily. Exercise therapy (resistance training three times a we
Sukonavi will be used solely for data collection purposes.

Sponsors

Nagao Masashi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Age: 50 or older but under 80 at the time of consent 2) Capable of physical activity 3) Hasegawa Dementia Scale score: 21 or higher 4) 6-minute walk test: 200 m or longer 5) Person who can prepare a smartphone and an email address and consent to downloading the necessary program onto the smartphone 6) Person who are determined by the principal investigator (or sub-investigator) to be able to appropriately evaluate the efficacy and safety of this study based on the inclusion criteria and exclusion criteria

Exclusion criteria

Exclusion criteria: 1) Unable of exercise therapy or exercise tolerance testing 2) Any comorbidities that would interfere with exercise therapy 3) Awaiting heart transplantation or other major surgery scheduled within one year of consent 4) Person who regularly engage in vigorous exercise 5) Person who are determined to be unsuitable for this trial by the principal investigator (or sub-investigator)

Design outcomes

Primary

MeasureTime frame
Change in walking distance in the 6-minute walk test approximately 3 months after the start of intervention

Secondary

MeasureTime frame
- Change in grip strength - Change in cytokine array of T cells - Changes in inflammatory cytokines, IL-6 orTNF-alpha - Change in Hasegawa Dementia Scale - Change in pulse rate by Sukonavi - Rate of serious adverse events

Contacts

Public ContactMasashi Nagao

Juntendo University

nagao@juntendo.ac.jp+81-3-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026